Efficacy & safety

VYZULTA achieved superior IOP reduction vs Timolol 0.5% and Xalatan (latanoprost) 0.005% as demonstrated in clinical trials1-4

VYZULTA delivered significantly greater mean IOP reduction vs Xalatan (latanoprost) 0.005% in the phase 2 dose-ranging VOYAGER study1

Reduction in mean diurnal IOP from baseline at Day 281

Voyager study design
Voyager study design

of VYZULTA patients achieved a ≥2 mmHg IOP reduction
vs Xalatan 0.005% mean diurnal IOP reduction2*

*Post-hoc analysis. Xalatan (latanoprost) 0.005% mean diurnal IOP reduction of 7.8 mmHg.

See Dr. Bacharach explain the VOYAGER study

See Dr. Bacharach explain the VOYAGER study

VYZULTA was noninferior vs Timolol 0.5% at all tested time points in the phase 3 APOLLO and LUNAR studies3,4

Mean IOP reduction of up to 9.1 and 8.8 mmHg from baseline with VYZULTA, respectively3,4

In APOLLO, baseline mean diurnal IOP in patients on VYZULTA was 26.7 mmHg vs 26.5 mmHg in patients on Timolol 0.5%3

APOLLO: VYZULTA demonstrated superior IOP reduction
vs Timolol 0.5% at Month 3

Apollo Study Chart

In LUNAR, baseline mean diurnal IOP in patients on VYZULTA was
26.6 mmHg vs 26.4 mmHg in patients on Timolol 0.5%4

LUNAR: VYZULTA demonstrated superior IOP reduction
vs Timolol 0.5% at Month 3

Apollo Study Chart

VYZULTA demonstrated superior IOP reductions vs Timolol 0.5% at 17 out of 18 time points3,4

See Dr. Radcliffe, Dr. Mosaed, and Dr. Al-Aswad explain the APOLLO and LUNAR studies

See Dr. Radcliffe, Dr. Mosaed, and Dr. Al-Aswad explain the APOLLO and LUNAR studies

VYZULTA demonstrated significant long-term
IOP reduction at 12 months5†

VYZULTA reduced mean IOP of 19.6 mmHg to
14.4 mmHg at Year 1

Voyager study design
Voyager study design

Majority of patients had baseline IOP ≤21.0 mmHg5

See Dr. Teymoorian explain the JUPITER study

See Dr. Teymoorian explain the JUPITER study

In APOLLO and LUNAR: 6 out of 811 patients treated with VYZULTA
discontinued treatment due to ocular adverse events3,4,6

Less than 1% discontinued due to ocular adverse reactions6

  • 0.6% of patients discontinued therapy due to ocular adverse events, including hyperemia, conjunctival irritation, eye irritation, eye pain, conjunctival edema, vision blurred, punctate keratitis, and foreign body sensation

Most common adverse reactions3,7‡

Voyager study design
safty chart

Pooled results from the APOLLO and LUNAR studies: ocular adverse reactions occurring in ≥2% of study eyes.3,7

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)
1. Weinreb RN, Ong T, Scassellati SB, Vittitow JL, Singh K, Kaufman PL. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738-745.
2. Data on File. Bausch & Lomb Incorporated.
3. Weinreb RN, Sforzolini BS, Vittitow J, Liebmann J. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123(5):965-973.
4. Medeiros FA, Martin KR, Peace J, Sforzolini BS, Vittitow JL, Weinreb RN. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016;168:250-259.
5. Kawase K, Vittitow JL, Weinreb RN, Araie M. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther. 2016;33(9):1612-1627.
6. VYZULTA Prescribing Information. Bausch & Lomb Incorporated.
7. Weinreb RN, Liebman JM, Martin KR, et al. Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma. 2018;27:7-15.

SEE MORE

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation